YHO-13177
目录号: PL02891 纯度: ≥98%
CAS No. :912287-56-0
商品编号 规格 价格 会员价 是否有货 数量
PL02891-5mg 5mg ¥1261.09 请登录
PL02891-10mg 10mg ¥1854.55 请登录
PL02891-50mg 50mg ¥6181.82 请登录
PL02891-100mg 100mg ¥10509.09 请登录
PL02891-200mg 200mg 询价 询价
PL02891-500mg 500mg 询价 询价
PL02891-10mM*1mLinDMSO 10mM*1mLinDMSO ¥1387.20 请登录
Medlife所售产品仅用于科学研究(非临床研究),非药品不可食用,不可用于人体或动物的临床诊断和治疗,我们不为个人提供产品及服务。产品COA等资料,可至下方“质量控制”中下载。
中文名称
YHO-13177
中文别名
YHO-13177
英文名称
YHO-13177
英文别名
YHO-13177;(Z)-2-(3,4-dimethoxyphenyl)-3-(5-(4-hydroxypiperidin-1-yl)thiophen-2-yl)acrylonitrile;(Z)-2-(3,4-dimethoxyphenyl)-3-[5-(4-hydroxypiperidin-1-yl)thiophen-2-yl]prop-2-enenitrile;s6715;(Z)-2-(3,4-dimethoxy-phenyl)-3-[5-(4-hydroxy-piperidin-1-yl)-thiophen-2-yl]-acrylonitrile;(αZ)-α-[[5-(4-Hydroxy-1-piperidinyl)-2-thienyl]methylene]-3,4-dimethoxybenzeneacetonitrile (ACI);(Z)-2-(3,4-Dimethoxyphenyl)-3-[5-(4-hydroxypiperidin-1-yl)thiophen-2-yl]-2-propenenitrile;YHO 13177
Cas No.
912287-56-0
分子式
C20H22N2O3S
分子量
370.47
包装储存
Powder -20°C 3 years;4°C 2 years
产品详情
YHO-13177是高活性乳腺癌耐药蛋白多药转运通道(BCRP)抑制剂,可增强SN-38活性且对P-gp无作用。
生物活性
YHO-13177 is a potent and specific inhibitor of BCRP; potentiated the cytotoxicity of SN-38 in cancer cells and no effect on P-glycoprotein–mediated paclitaxel resistance in MDR1-transduced human leukemia K562 cells. IC50 value: Target: BCRP inhibitor in vitro: YHO-13177 potentiated the cytotoxicity of SN-38, mitoxantrone, and topotecan in both BCRP-transduced human colon cancer HCT116 (HCT116/BCRP) cells and SN-38–resistant human lung cancer A549 (A549/SN4) cells that express BCRP, but had little effect in the parental cells. In addition, YHO-13177 potentiated the cytotoxicity of SN-38 in human lung cancer NCI-H460 and NCI-H23, myeloma RPMI-8226, and pancreatic cancer AsPC-1 cells that intrinsically expressed BCRP. In contrast, it had no effect on P-glycoprotein–mediated paclitaxel
性状
Solid
运输条件
Room temperature in continental US; may vary elsewhere.
储存方式
Powder -20°C 3 years;4°C 2 years
参考文献
[1]. Yamazaki R, et al. Novel acrylonitrile derivatives, YHO-13177 and YHO-13351, reverse BCRP/ABCG2-mediated drug resistance in vitro and in vivo. Mol Cancer Ther. 2011 Jul;10(7):1252-63.
溶解度数据
In Vitro: DMSO : 33.33 mg/mL (89.97 mM; Need ultrasonic)配制储备液
搜索质检报告(COA)

1:一般建议:溶解度为Medlife测试数据,可能与文献描述存在差异。这是由于生产工艺和批次不同产生的正常现象。为了使其更好的溶解,请用37℃加热试管并在超声波水浴中震动片刻。不同批次产品溶解度各有差异,仅做参考,具体以实验方案为准。

2:储存条件:粉末-20°C一般情况可以保存3年,溶于溶剂-80°C一般情况可以保存1年。不同产品及不同批次产品可能存在差异,请细致阅读产品信息,并辅助参考相关文献描述。

The molarity calculator equation
Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)
The dilution calculator equation
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2